SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-328951
Filing Date
2021-11-15
Accepted
2021-11-15 07:44:33
Documents
15
Period of Report
2021-11-15
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d90613d8k.htm   iXBRL 8-K 24995
2 EX-99.1 d90613dex991.htm EX-99.1 3953
6 GRAPHIC g90613dsp088.jpg GRAPHIC 220402
7 GRAPHIC g90613dsp089.jpg GRAPHIC 202255
  Complete submission text file 0001193125-21-328951.txt   738954

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA inzy-20211115.xsd EX-101.SCH 2889
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE inzy-20211115_lab.xml EX-101.LAB 18888
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE inzy-20211115_pre.xml EX-101.PRE 11858
8 EXTRACTED XBRL INSTANCE DOCUMENT d90613d8k_htm.xml XML 3474
Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Filer) CIK: 0001693011 (see all company filings)

IRS No.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39397 | Film No.: 211406373
SIC: 2834 Pharmaceutical Preparations